{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T21:43:32Z","timestamp":1794951812082,"version":"4.9.1"},"reference-count":57,"publisher":"Elsevier BV","issue":"31","license":[{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100018818","name":"National Research, Development and Innovation Office","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100018818","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007601","name":"Horizon 2020","doi-asserted-by":"publisher","award":["825828"],"award-info":[{"award-number":["825828"]}],"id":[{"id":"10.13039\/501100007601","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007601","name":"Horizon 2020","doi-asserted-by":"publisher","award":["952520"],"award-info":[{"award-number":["952520"]}],"id":[{"id":"10.13039\/501100007601","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011019","name":"Nemzeti Kutat\u00e1si Fejleszt\u00e9si \u00e9s Innov\u00e1ci\u00f3s Hivatal","doi-asserted-by":"publisher","award":["2020-1.1.6-J\u00d6V\u0150-2021-00013"],"award-info":[{"award-number":["2020-1.1.6-J\u00d6V\u0150-2021-00013"]}],"id":[{"id":"10.13039\/501100011019","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2023,7]]},"DOI":"10.1016\/j.vaccine.2023.06.009","type":"journal-article","created":{"date-parts":[[2023,6,5]],"date-time":"2023-06-05T03:38:20Z","timestamp":1685936300000},"page":"4561-4570","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":116,"title":["Role of anti-polyethylene glycol (PEG) antibodies in the allergic reactions to PEG-containing Covid-19 vaccines: Evidence for immunogenicity of PEG"],"prefix":"10.1016","volume":"41","author":[{"given":"Gergely Tibor","family":"Kozma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tam\u00e1s","family":"M\u00e9sz\u00e1ros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petra","family":"Ber\u00e9nyi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R\u00e9ka","family":"Facsk\u00f3","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zs\u00f3fia","family":"Patk\u00f3","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Csaba Zs.","family":"Ol\u00e1h","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrienne","family":"Nagy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tam\u00e1s Gyula","family":"F\u00fcl\u00f6p","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathryn Anne","family":"Glatter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tam\u00e1s","family":"Radovits","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B\u00e9la","family":"Merkely","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1738-797X","authenticated-orcid":false,"given":"J\u00e1nos","family":"Szebeni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2023.06.009_b0005","doi-asserted-by":"crossref","first-page":"5798","DOI":"10.1016\/j.vaccine.2022.08.036","article-title":"Serious adverse events of special interest following mRNA COVID-19 vaccination in randomized trials in adults","volume":"40","author":"Fraiman","year":"2022","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2023.06.009_b0010","article-title":"mRNA vaccines to prevent COVID-19 disease and reported allergic reactions: Current evidence and suggested approach","author":"Banerji","year":"2020","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.vaccine.2023.06.009_b0015","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.25524","article-title":"Assessment of allergic and anaphylactic reactions to mRNA COVID-19 vaccines with confirmatory testing in a US regional health system","volume":"4","author":"Warren","year":"2021","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.vaccine.2023.06.009_b0020","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1111\/ajt.16517","article-title":"Allergic reactions including anaphylaxis after receipt of the first dose of Moderna COVID-19 vaccine - United States, December 21, 2020-January 10, 2021","volume":"21","author":"Shimabukuro","year":"2021","journal-title":"Am J Transplant"},{"key":"10.1016\/j.vaccine.2023.06.009_b0025","doi-asserted-by":"crossref","DOI":"10.1001\/jama.2021.0600","article-title":"Allergic reactions including anaphylaxis after receipt of the first dose of Pfizer-BioNTech COVID-19 vaccine","author":"Shimabukuro","year":"2021","journal-title":"JAMA"},{"key":"10.1016\/j.vaccine.2023.06.009_b0030","article-title":"Allergic reactions to current available COVID-19 vaccinations","volume":"9","author":"Kounis","year":"2021","journal-title":"Pathophysiol, Causality, Therap Considerations Vaccines (Basel)"},{"key":"10.1016\/j.vaccine.2023.06.009_b0035","article-title":"Pseudo-anaphylactic reactions to Pfizer BNT162b2 vaccine: Report of 3 cases of anaphylaxis post Pfizer BNT162b2 vaccination","volume":"9","author":"Lim","year":"2021","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.vaccine.2023.06.009_b0040","doi-asserted-by":"crossref","first-page":"2916","DOI":"10.1111\/all.14958","article-title":"Anaphylaxis to the first dose of mRNA SARS-CoV-2 vaccines: Don't give up on the second dose!","volume":"76","author":"Krantz","year":"2021","journal-title":"Allergy"},{"key":"10.1016\/j.vaccine.2023.06.009_b0045","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1001\/jama.2021.3976","article-title":"Acute allergic reactions to mRNA COVID-19 vaccines","volume":"325","author":"Blumenthal","year":"2021","journal-title":"JAMA"},{"key":"10.1016\/j.vaccine.2023.06.009_b0050","article-title":"Pfizer-BioNTech COVID-19 vaccine tolerance in allergic versus non-allergic individuals","volume":"9","author":"Nittner-Marszalska","year":"2021","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.vaccine.2023.06.009_b0055","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.22255","article-title":"Prevalence of allergic reactions after Pfizer-BioNTech COVID-19 vaccination among adults with high allergy risk","volume":"4","author":"Shavit","year":"2021","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.vaccine.2023.06.009_b0060","doi-asserted-by":"crossref","first-page":"2969","DOI":"10.1080\/21645515.2021.1917236","article-title":"Preliminary evidence on the safety profile of BNT162b2 (Comirnaty): new insights from data analysis in EudraVigilance and adverse reaction reports from an Italian health facility","volume":"17","author":"Gringeri","year":"2021","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.vaccine.2023.06.009_b0065","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaci.2021.04.002","article-title":"Potential mechanisms of anaphylaxis to COVID-19 mRNA vaccines","author":"Risma","year":"2021","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.vaccine.2023.06.009_b0070","doi-asserted-by":"crossref","DOI":"10.3389\/falgy.2021.715844","article-title":"Anaphylaxis to Pfizer\/BioNTech mRNA COVID-19 vaccine in a patient with clinically confirmed PEG allergy","volume":"2","author":"McSweeney","year":"2021","journal-title":"Front Allergy"},{"key":"10.1016\/j.vaccine.2023.06.009_b0075","doi-asserted-by":"crossref","first-page":"3308","DOI":"10.1016\/j.jaip.2021.06.010","article-title":"First-dose mRNA COVID-19 vaccine allergic reactions: Limited role for excipient skin testing","volume":"9","author":"Wolfson","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.vaccine.2023.06.009_b0080","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1007\/s40259-022-00536-8","article-title":"Allergic reactions to COVID-19 vaccines: Risk factors, frequency, mechanisms and management","volume":"36","author":"Luxi","year":"2022","journal-title":"BioDrugs"},{"key":"10.1016\/j.vaccine.2023.06.009_b0085","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1038\/s41565-022-01071-x","article-title":"Applying lessons learned from nanomedicines to understand rare hypersensitivity reactions to mRNA-based SARS-CoV-2 vaccines","volume":"17","author":"Szebeni","year":"2022","journal-title":"Nat Nanotechnol"},{"key":"10.1016\/j.vaccine.2023.06.009_b0090","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaip.2022.07.012","article-title":"Reporting of allergic reactions during Pfizer-BioNTech BNTT162B2 vaccination in Israel","author":"Anis","year":"2022","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.vaccine.2023.06.009_b0095","unstructured":"Pfizer Responds to Research Claims. Press release on January 27, 2023 - 08:00pm. https:\/\/wwwpfizercom\/news\/announcements\/pfizer-responds-research-claims; 2023."},{"key":"10.1016\/j.vaccine.2023.06.009_b0100","article-title":"Anaphylaxis to the first COVID-19 vaccine: is polyethylene glycol (PEG) the culprit?","author":"Garvey","year":"2020","journal-title":"Br J Anesthesia"},{"key":"10.1016\/j.vaccine.2023.06.009_b0105","article-title":"Suspicions grow that nanoparticles in Pfizer\u2019s COVID-19 vaccine trigger rare allergic reactions","author":"Vrieze","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.vaccine.2023.06.009_b0110","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1111\/cea.13874","article-title":"Polyethylene glycol (PEG) is a cause of anaphylaxis to the Pfizer\/BioNTech mRNA COVID-19 vaccine","volume":"51","author":"Sellaturay","year":"2021","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.vaccine.2023.06.009_b0115","doi-asserted-by":"crossref","DOI":"10.1021\/acsnano.2c04543","article-title":"Anti-PEG antibodies boosted in humans by SARS-CoV-2 lipid nanoparticle mRNA vaccine","author":"Ju","year":"2022","journal-title":"ACS Nano"},{"key":"10.1016\/j.vaccine.2023.06.009_b0120","article-title":"mRNA-1273 but not BNT162b2 induces antibodies against polyethylene glycol (PEG) contained in mRNA-based vaccine formulations","author":"Carreno","year":"2022","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2023.06.009_b0125","doi-asserted-by":"crossref","unstructured":"Wang H, Wang Y, Yuan C, Xu X, Zhou W, Huang Y, et al. Polyethylene glycol (PEG)-associated immune responses triggered by clinically relevant lipid nanoparticles. 2023: 2022.11.24.516986.","DOI":"10.1101\/2022.11.24.516986"},{"key":"10.1016\/j.vaccine.2023.06.009_b0130","article-title":"Premature drug release from polyethylene glycol (PEG)-coated liposomal doxorubicin via formation of the membrane attack complex","author":"Chen","year":"2020","journal-title":"ACS Nano"},{"key":"10.1016\/j.vaccine.2023.06.009_b0135","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/j.jconrel.2021.11.042","article-title":"Anti-PEG antibodies compromise the integrity of PEGylated lipid-based nanoparticles via complement","volume":"341","author":"Estape Senti","year":"2021","journal-title":"J Control Release"},{"key":"10.1016\/j.vaccine.2023.06.009_b0140","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.ijpharm.2007.11.005","article-title":"Accelerated blood clearance (ABC) phenomenon upon repeated injection of PEGylated liposomes","volume":"354","author":"Ishida","year":"2008","journal-title":"Int J Pharm"},{"key":"10.1016\/j.vaccine.2023.06.009_b0145","series-title":"Immune effects of biopharmaceuticals and nanomedicines","first-page":"771","article-title":"Accelerated blood clearance phenomenon and complement activation-related pseudoallergy: Two sides of the same coin","author":"Abu Lila","year":"2018"},{"key":"10.1016\/j.vaccine.2023.06.009_b0150","doi-asserted-by":"crossref","DOI":"10.1186\/ar4500","article-title":"Induced and pre-existing anti-polyethylene glycol antibody in a trial of every 3-week dosing of pegloticase for refractory gout, including in organ transplant recipients","volume":"16","author":"Hershfield","year":"2014","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.vaccine.2023.06.009_b0155","doi-asserted-by":"crossref","DOI":"10.1186\/s13075-017-1396-8","article-title":"Frequency, distribution and immunologic nature of infusion reactions in subjects receiving pegloticase for chronic refractory gout","volume":"19","author":"Calabrese","year":"2017","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.vaccine.2023.06.009_b0160","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1016\/j.jaci.2015.10.034","article-title":"Pre-existing anti-polyethylene glycol antibody linked to first-exposure allergic reactions to pegnivacogin, a PEGylated RNA aptamer","volume":"137","author":"Ganson","year":"2016","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.vaccine.2023.06.009_b0165","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.1016\/j.jaci.2016.04.058","article-title":"Pre-existing anti-PEG antibodies are associated with severe immediate allergic reactions to pegnivacogin, a PEGylated aptamer","volume":"138","author":"Povsic","year":"2016","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.vaccine.2023.06.009_b0170","doi-asserted-by":"crossref","DOI":"10.1002\/cpdd.1225","article-title":"Clinical impact of antipolyethylene glycol (PEG) antibody in hematological patients administered PEGylated-granulocyte colony-stimulating factor","author":"Okada","year":"2023","journal-title":"Clin Pharmacol Drug Dev"},{"key":"10.1016\/j.vaccine.2023.06.009_b0175","doi-asserted-by":"crossref","first-page":"9315","DOI":"10.1021\/acsnano.9b03942","article-title":"Pseudo-anaphylaxis to polyethylene glycol (PEG)-coated liposomes: Roles of anti-PEG IgM and complement activation in a porcine model of human infusion reactions","volume":"13","author":"Kozma","year":"2019","journal-title":"ACS Nano"},{"key":"10.1016\/j.vaccine.2023.06.009_b0180","doi-asserted-by":"crossref","DOI":"10.3390\/vaccines9070700","article-title":"Development of SARS-CoV-2 specific IgG and virus-neutralizing antibodies after infection with variants of concern or vaccination","author":"Neumann","year":"2021","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.vaccine.2023.06.009_b0185","doi-asserted-by":"crossref","DOI":"10.1186\/s12916-021-02231-x","article-title":"Humoral immune response after different SARS-CoV-2 vaccination regimens","volume":"20","author":"Rose","year":"2022","journal-title":"BMC Med"},{"key":"10.1016\/j.vaccine.2023.06.009_b0190","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.addr.2020.07.024","article-title":"Anti-PEG antibodies: Properties, formation, testing and role in adverse immune reactions to PEGylated nano-biopharmaceuticals","volume":"154\u2013155","author":"Kozma","year":"2020","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.vaccine.2023.06.009_b0195","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1007\/s11357-021-00495-y","article-title":"A naturally hypersensitive porcine model may help understand the mechanism of COVID-19 mRNA vaccine-induced rare (pseudo) allergic reactions: complement activation as a possible contributing factor","volume":"44","author":"Dezsi","year":"2022","journal-title":"Geroscience."},{"key":"10.1016\/j.vaccine.2023.06.009_b0200","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1002\/1097-0320(20010901)45:1<47::AID-CYTO1143>3.0.CO;2-A","article-title":"Probability binning comparison: a metric for quantitating multivariate distribution differences","volume":"45","author":"Roederer","year":"2001","journal-title":"Cytometry"},{"key":"10.1016\/j.vaccine.2023.06.009_b0205","doi-asserted-by":"crossref","first-page":"5675","DOI":"10.1016\/j.vaccine.2007.02.064","article-title":"Anaphylaxis: case definition and guidelines for data collection, analysis, and presentation of immunization safety data","volume":"25","author":"Ruggeberg","year":"2007","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2023.06.009_b0210","doi-asserted-by":"crossref","first-page":"4406","DOI":"10.1016\/j.vaccine.2016.07.019","article-title":"Adverse events following pandemic influenza A (H1N1) 2009 monovalent and seasonal influenza vaccinations during the 2009\u20132010 season in the active component U.S. military and civilians aged 17\u201344years reported to the Vaccine Adverse Event Reporting System","volume":"34","author":"Bardenheier","year":"2016","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2023.06.009_b0215","doi-asserted-by":"crossref","first-page":"125","DOI":"10.15585\/mmwr.mm7004e1","article-title":"Allergic reactions including anaphylaxis after receipt of the first dose of moderna COVID-19 vaccine - United States, December 21, 2020-January 10, 2021","volume":"70","author":"Food and Drug Administration","year":"2021","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.vaccine.2023.06.009_b0220","unstructured":"Our-World-In-Data Internet link. Covid-vaccine-doses-by-manufacturer. https:\/\/ourworldindataorg\/grapher\/covid-vaccine-doses-by-manufacturer; 2023."},{"key":"10.1016\/j.vaccine.2023.06.009_b0225","doi-asserted-by":"crossref","unstructured":"Armstrong JK. The occurrence, induction, specificity and potential effect of antibodies against poly(ethylene glycol). In: Veronese FM, editor. PEGylated protein drugs: Basic science and clinical applications. Birkh\u00e4user Verlag\/Switzerland; 2009. p. 147-68.","DOI":"10.1007\/978-3-7643-8679-5_9"},{"key":"10.1016\/j.vaccine.2023.06.009_b0230","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1517\/17425247.2012.720969","article-title":"Antibodies against polyethylene glycol in healthy subjects and in patients treated with PEG-conjugated agents","volume":"9","author":"Garay","year":"2012","journal-title":"Expert Opin Drug Deliv"},{"key":"10.1016\/j.vaccine.2023.06.009_b0235","doi-asserted-by":"crossref","first-page":"10661","DOI":"10.1021\/acs.analchem.6b03109","article-title":"Measurement of pre-existing IgG and IgM antibodies against polyethylene glycol in healthy individuals","volume":"88","author":"Chen","year":"2016","journal-title":"Anal Chem"},{"key":"10.1016\/j.vaccine.2023.06.009_b0240","doi-asserted-by":"crossref","first-page":"2239","DOI":"10.1007\/s11095-016-1961-x","article-title":"The mystery of antibodies against polyethylene glycol (PEG) - what do we know?","volume":"33","author":"Lubich","year":"2016","journal-title":"Pharm Res"},{"key":"10.1016\/j.vaccine.2023.06.009_b0245","doi-asserted-by":"crossref","first-page":"14022","DOI":"10.1021\/acsnano.1c05922","article-title":"Polyethylene glycol immunogenicity: Theoretical, clinical, and practical aspects of anti-polyethylene glycol antibodies","volume":"15","author":"Chen","year":"2021","journal-title":"ACS Nano"},{"key":"10.1016\/j.vaccine.2023.06.009_b0250","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/j.jconrel.2022.12.039","article-title":"Anti-PEG antibodies before and after a first dose of Comirnaty(R) (mRNA-LNP-based SARS-CoV-2 vaccine)","volume":"354","author":"Bavli","year":"2023","journal-title":"J Control Release"},{"key":"10.1016\/j.vaccine.2023.06.009_b0255","unstructured":"The allergist. Medications containing PEG\/Polysorbate. The allergist; 2021 https:\/\/theallergist.wordpress.com\/2021\/03\/02\/medications-containing-peg-polysorbate\/."},{"key":"10.1016\/j.vaccine.2023.06.009_b0260","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.jconrel.2023.01.012","article-title":"Investigation of anti-PEG antibody response to PEG-containing cosmetic products in mice","volume":"354","author":"Ibrahim","year":"2023","journal-title":"J Control Release"},{"key":"10.1016\/j.vaccine.2023.06.009_b0265","article-title":"Safe administration of SARS-CoV-2 vaccine after desensitization to a biologic containing polysorbate 80 in a patient with polyethylene glycol-induced severe anaphylaxis and sensitization to polysorbate 80","volume":"0","author":"Nin-Valencia","year":"2022","journal-title":"J Investig Allergol Clin Immunol"},{"key":"10.1016\/j.vaccine.2023.06.009_b0270","doi-asserted-by":"crossref","DOI":"10.1186\/s40360-022-00591-5","article-title":"Macromolecules in polysorbate 80 for injection: an important cause of anaphylactoid reactions","volume":"23","author":"Li","year":"2022","journal-title":"BMC Pharmacol Toxicol"},{"key":"10.1016\/j.vaccine.2023.06.009_b0275","unstructured":"Drugs.com. Polysorbate-80. https:\/\/wwwdrugscom\/inactive\/polysorbate-80-372html#ref1; 2022."},{"key":"10.1016\/j.vaccine.2023.06.009_b0280","doi-asserted-by":"crossref","first-page":"7682","DOI":"10.1021\/acsnano.0c03648","article-title":"Complement activation: A potential threat on the safety of poly(ethylene glycol)-coated nanomedicines","volume":"14","author":"Gabizon","year":"2020","journal-title":"ACS Nano"},{"key":"10.1016\/j.vaccine.2023.06.009_b0285","doi-asserted-by":"crossref","first-page":"46","DOI":"10.15585\/mmwr.mm7002e1","article-title":"Allergic reactions including anaphylaxis after receipt of the first dose of Pfizer-BioNTech COVID-19 vaccine - United States, December 14\u201323, 2020","volume":"70","author":"FDA","year":"2021","journal-title":"MMWR Morb Mortal Wkly Rep"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X23006679?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X23006679?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T11:29:21Z","timestamp":1759404561000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X23006679"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7]]},"references-count":57,"journal-issue":{"issue":"31","published-print":{"date-parts":[[2023,7]]}},"alternative-id":["S0264410X23006679"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2023.06.009","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2023,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Role of anti-polyethylene glycol (PEG) antibodies in the allergic reactions to PEG-containing Covid-19 vaccines: Evidence for immunogenicity of PEG","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2023.06.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}